# Vascular Behçet Research Workflow

Use when Sir asks about vascular Behçet, thromboses, thrombophlebitis, anticoagulation, Colchicin, Eliquis/Apixaban, Adalimumab/Hyrimoz/Humira, or TNF inhibitors.

## Canonical local vault
- Research vault: `~/jarvis_memory/health/behcet_vascular_research/`
- Main synthesis: `~/jarvis_memory/health/behcet_vascular_research/evidence_summary.md`
- Study cards: `~/jarvis_memory/health/behcet_vascular_research/studies/`
- Guideline/source cards: `~/jarvis_memory/health/behcet_vascular_research/sources/`

## Current durable clinical synthesis
- Behçet-associated thrombosis is commonly framed as inflammation-induced thrombosis; immunosuppression/biologic disease control is the core mechanism-targeted treatment.
- Adalimumab is a plausible escalation for venous vascular Behçet, especially active/recurrent venous thrombosis or superficial thrombophlebitis despite conventional therapy.
- Do not infer that Eliquis/Apixaban can be reduced just because Adalimumab/Hyrimoz is started. Reduction needs clinician-led criteria: no new thrombosis/SVT, controlled symptoms, CRP/BSG, stable/improved imaging, aneurysm status, and Rheumatology + Angiology/Hemostasis agreement.
- EULAR 2018: anticoagulants may be added to immunosuppression if bleeding risk is low and pulmonary artery aneurysms are ruled out.
- Newer 2024/2025 evidence suggests IS + anticoagulation may reduce recurrent thrombosis in selected patients, but evidence is mostly retrospective and not DOAC/Apixaban-specific.
- Colchicin is generally more relevant to mucocutaneous/joint and superficial inflammatory manifestations; tapering is more plausible after stable biologic response than immediate change.

## Key saved studies
- Emmi et al. 2018 — Adalimumab-based treatment vs DMARDs for venous thrombosis in Behçet; 70 patients; PubMed 29676522; DOI 10.1002/art.40531.
- Kaban & Harman 2023 — Adalimumab add-on in two Behçet leg-ulcer/venous disease cases; PubMed 37534898; DOI 10.1093/mrcr/rxad044.
- Erol et al. 2024 — IS + anticoagulation associated with lower recurrent thrombosis than IS alone; PubMed 38357865.
- 2025 reviews/meta-analysis in the vault summarize anticoagulation + immunosuppression signals.

## Hyrimoz / Adalimumab start counseling pattern
- No preferred pharmacologic time of day; first dose is pragmatically best morning/early afternoon on a quiet day so reactions/questions can be handled while clinic/pharmacy are open.
- Avoid starting during fever or active infection; lab/TB/hepatitis screening should be confirmed as physician-cleared.
- For Eliquis users: no main direct interaction, but expect easier bruising/hematoma at injection site; apply gentle pressure, do not rub, rotate sites, avoid bruised/inflamed skin.
- Emphasize consistent dosing interval, correct refrigeration/no freezing/no shaking, room-temperature warm-up before injection, infection vigilance, no live vaccines without physician planning.

## Output style for Sir
- German with English clinical terms.
- Be practical and risk-framed; distinguish evidence, forum anecdotes, and direct medical advice.
- Keep explicit: this supports Arztgespräch and monitoring, not autonomous medication changes.